Navigation Links
Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
Date:7/25/2013

ny's stock, resulting in damage to Class Members when the truth was revealed.  Defendants deny all of Plaintiffs' allegations.

IF YOU PURCHASED PACB COMMON STOCK ON OR ABOUT OCTOBER 27, 2010 THROUGH AND INCLUDING SEPTEMBER 20, 2011, INCLUDING IF YOU PURCHASED THE COMPANY'S STOCK PURSUANT AND/OR TRACEABLE TO THE COMPANY'S REGISTRATION STATEMENT AND PROSPECTUS FILED WITH THE SEC IN CONNECTION WITH THE COMPANY'S OCTOBER 27, 2010 IPO, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS ACTION.

To share in the distribution of the Settlement Fund, you must establish your rights by filing a Proof of Claim on or before October 16, 2013.  Your failure to submit your Proof of Claim by October 16, 2013 will subject your claim to rejection and preclude your receiving any of the recovery in connection with the Settlement of this Action.  If you are a member of the Class and do not request exclusion therefrom, you will be bound by the Settlement and any judgment and Release entered in the Action, including, but not limited to, the Final Order, whether or not you submit a Proof of Claim.

If you have not received a copy of the Notice, which more completely describes the Settlement and your rights thereunder (including your right to object to the Settlement), and a Proof of Claim form, you may obtain these documents, as well as a copy of the Stipulation (which among other things contains definitions for the defined terms used in this Summary Notice) and other settlement documents, online at www.PacificBiosciencesSecuritiesLitigation.com, or by writing to:

Pacific Biosciences Securities Litigation Settlement
c/o GCG
P.O. Box 35072
Seattle, WA 98124-3508
Phone:  (866) 297-1225

Inquiries should NOT be directed to Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice
'/>"/>

SOURCE Robbins Geller Rudman & Dowd LLP; Scott+Scott, Attorneys at Law, LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality
2. Asia-Pacific Gesture Recognition & Touchless Sensing Market (2013 - 2018)
3. Bert L. & N. Kuggie Vallee Foundation announces first recipients of its Young Investigator Awards
4. Geology tracks eruptions, earthquakes, erosion, extinctions & more
5. NREL research earns 3 prestigious R&D 100 Awards
6. Frost & Sullivan: Renewable Energy Targets Help Sustain European Biopower Market amid Economic Uncertainty
7. Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market
8. AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life
9. E3 Forum -- Education, Employment & Entrepreneurship on a Global context
10. Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases
11. Global Biometric Systems Market Forecast & Opportunities, 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... researchers hope to take a healthy salad up a ... of breast cancer in leafy greens. , "In the ... either by eating the salad or making a pill ... of biomedical engineering at Case Western Reserve School of ... G. Komen breast cancer organization is funding the research ...
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... available in German . ... animal behaviour that is subject to annual rhythms is controlled by ... time, in many cases it is still unclear how far genes ... also applied to the common buzzard and its migration from parental ...
... , This news release is available in ... are bad at getting a grip on collective risks. Climate change ... so far not led to specific measures. The reason for this ... than to investing in future quality of life. Therefore, ...
... physicians and biologists alike - even though it is well-established ... stages, immobility can all be traced back to the death ... neuron. The underlying cause of this cellular death is a ... external factors, most of the details of which are well-known. ...
Cached Biology News:The molecular clock of the common buzzard 2People don't put a high value on climate protection 2People don't put a high value on climate protection 3PD map: Putting together the pieces of the Parkinson's puzzle 2PD map: Putting together the pieces of the Parkinson's puzzle 3
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... 5 , - Data Presented ... York , ThromboGenics NV (Euronext Brussels: ... innovative medicines for eye,disease, vascular disease and cancer, today announces ... the treatment of,Diabetic Macular Edema (MIVI II DME). The data ...
... , LA JOLLA, Calif., Oct. 5 Transdel Pharmaceuticals, Inc. ... a conference call and audio webcast on Tuesday, October 6, ... of its Phase 3 clinical study for Ketotransdel®, a topical ... A press release will be issued on Tuesday, October 6, ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
Cached Biology Technology:ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 2Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
Request Info...
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Biology Products: